Syntekabio, an AI-based drug development company, announced on the 5th that it was officially invited to participate in the 39th JPMorgan Healthcare Conference held online on the 11th and 14th.
Syntekabio is the first domestic AI drug development company to participate in the 37th JPMorgan Healthcare Conference for 3 consecutive years since it was officially invited in 2019.
The JPMorgan Healthcare Conference is the world’s largest bio-investment event held in January every year, starting in 1983 and marking its 39th anniversary this year. This year, it will be held online in the aftermath of the spread of Corona 19 around the world, and more than 500 companies will participate and introduce each company’s research results and business strategies.
At this conference, Syntekabio will discuss its achievements to date and future collaboration plans, focusing on its own new drug pipeline, its own AI drug development platform technology, and genome precision medical service.
Syntekabio’s representative AI drug development platforms are’DeepMatcher’ and’NEOscan’.
Deep Matcher is an AI platform technology for discovery of synthetic new drug candidates and drug re-creation, and was used to derive immuno-anticancer drug candidates STB-C017 and Corona 19 drug re-creation candidates. Neoscan is an AI platform technology that predicts new antigens to treat cancer by inducing the immune response of cancer patients individually.
Syntekabio is going to establish joint R&D and partnership using AI platform technology through a one-on-one partnership meeting with global pharmaceutical bio companies and investors. The technology is already quickly recognized in the market, and it is planning to enter the global market in earnest.
Syntekabio President Tae-soon Kim said, “I have been participating in the JP Morgan Healthcare Conference for 3 consecutive years, and I am experiencing the increasing interest in AI drug development every year.” Through this, we expect to be able to promote a further business in the future.”